Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Harpoon Therapeutics Inc (HARP)

Harpoon Therapeutics Inc (HARP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Harpoon Therapeutics Inc 611 Gateway Boulevard Suite 400 SOUTH SAN FRANCISCO CA 94080 USA

www.harpoontx.com P: 650-443-7400

Description:

Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company developing a novel class of T cell engagers which harness the power of the body's immune system to treat patients suffering from cancer and other diseases. Using its proprietary Tri-specific T cell Activating Construct(TM) platform, they are developing a pipeline of novel T cell engagers, focused on the treatment of solid tumors and hematologic malignancies. Harpoon Therapeutics Inc. is based in San Francisco, United States.

Key Statistics

Overview:

Market Capitalization, $K 389,605
Enterprise Value, $K 337,995
Shares Outstanding, K 16,932
Annual Sales, $ 31,920 K
Annual Net Income, $ -67,730 K
Last Quarter Sales, $ 4,450 K
Last Quarter Net Income, $ -1,800 K
EBIT, $ -39,130 K
EBITDA, $ -36,380 K
60-Month Beta 2.11
% of Insider Shareholders 17.00%
% of Institutional Shareholders 74.01%
Float, K 14,054
% Float 83.00%
Short Volume Ratio 0.31

Growth:

1-Year Return 217.38%
3-Year Return -88.21%
5-Year Return -80.92%
5-Year Revenue Growth 4,395.77%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.46 on 11/09/23
Latest Earnings Date 03/25/24
Earnings Per Share ttm -8.76
EPS Growth vs. Prev Qtr -253.33%
EPS Growth vs. Prev Year 86.86%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 09/05/23

HARP Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -893.55%
Return-on-Assets % -45.98%
Profit Margin % -212.19%
Debt/Equity 0.00
Price/Sales 2.28
Price/Cash Flow N/A
Price/Book 20.82
Book Value/Share 1.10
Interest Coverage -2.59
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar